UNSPSC 51362003: Flurazepam

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHP475989U, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but generally known as flurazepam, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07744MIG.

UNSPSC 51362003 Flurazepam is a Commodity code that in practice captures pharmaceutical and medical supply procurement by state and local health authorities. However, the recent activity indexed under this code does not align with the code's nominal scope—the single recent opportunity on record is Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems, neither of which is flurazepam. The mismatch suggests either a classification error in the county's tagging or that flurazepam procurement through state and local channels is not currently surfacing in public opportunity records. Flurazepam is a controlled sedative-hypnotic pharmaceutical typically acquired through state health departments, corrections systems, or institutional healthcare procurement channels; when state and local bodies do buy it, the work typically flows through established pharmaceutical supply contracts or GPOs rather than standalone solicitations.

The single flagged opportunity—Seminole County's IFB60459723LAS, posted June 30, 2026 with response due July 26, 2026—represents opioid-antagonist and drug-disposal procurement rather than flurazepam itself. That IFB called for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; bidders were required to submit electronically, include all shipping costs, and demonstrate E-Verify compliance and drug-free workplace certification. Because the indexed opportunity does not substantively address flurazepam procurement, the code shows little relevant recent activity for business-development purposes. Firms targeting controlled-substance or psychiatric-pharmaceutical sales to state and local health systems should monitor state health department RFPs, corrections department procurement notices, and institutional healthcare GPO vehicles rather than relying on this code's current signal.